Thymus gland may hold key to preventing immune cell loss during lung cancer treatment

NCT ID NCT07564089

Ongoing Knowledge-focused Sponsor: You Peimeng Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the size and shape of the thymus gland, along with the radiation dose it receives, can predict a drop in immune cells (lymphocytes) during chest radiation for stage III lung cancer. Researchers will collect data from standard scans and blood tests of 450 adults receiving curative radiation, without changing their treatment. The goal is to find ways to design radiation plans that spare the immune system in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors design radiation treatments that better protect the immune system, potentially reducing side effects for future lung cancer patients.
What could go wrong: This is an observational study, so it does not test a new treatment. The findings may not lead to immediate changes in care, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NUMBER OF LYMPHOCYTES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphopenia non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NUMBER OF LYMPHOCYTES RADIATION-INDUCED LYMPHOPENIA THYMUS DOSIMETRIC

Contacts and locations

Locations

Jiangxi Cancer Hospital

Nanchang, Jiangxi, 330000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.